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Background and objectives: The superiority of atypical antipsychotics (also known as second-generation anti-
psychotics (SGAs)) over typical antipsychotics (ﬁrst generation antipsychotics (FGAs)) for negative symptom
control in schizophrenic patients is widely debated. The objective of this study was to characterize the time
course of the scores of the 3 subscales (positive, negative, general) of the Positive and Negative Syndrome
Scale (PANSS) after treatment of patients with antipsychotics, and to compare the control of negative symptom
by SGAs versus a FGA (haloperidol) using pharmacokinetic and pharmacodynamic (PKPD) modelling. In addi-
tion, to obtain insight in the relationship between the clinical efﬁcacy and the in vitro and in vivo receptor phar-
macology proﬁles, the D2 and 5-HT2A receptor occupancy levels of antipsychotics were related to the effective
concentrations.
Methods: The PKPD model structure developed earlier (part I) was used to quantify the drug effect using the 3
PANSS subscales. The maximum drug effect sizes (Emax) of oral SGAs (risperidone, olanzapine, ziprasidone, and
paliperidone) across PANSS subscales were comparedwith that of haloperidol, while accounting for the placebo
effect. Using the estimates of PKPD model parameters, the effective concentrations (Ceff) needed to achieve 30%
reduction in the PANSS subscales were computed. Calculated effective concentrations were then correlated
with receptor pharmacology proﬁles.
Results: Positive symptoms of schizophrenia responded well to all antipsychotics. Olanzapine showed a better
effect towards negative symptoms than the other SGAs and haloperidol. Dropout modelling results showed
that the probability of a patient dropping out froma trialwas associatedwith all subscales, butwasmore strongly
correlated with the positive subscale than with the negative or the general subscales. Our results suggest that
different levels of D2 or 5-HT2A receptor occupancy are required to achieve improvement in PANSS subscales.
Conclusions: This PKPD modelling approach can be helpful to differentiate the effect of antipsychotics across
the different symptom domains of schizophrenia. Our analysis revealed that olanzapine seems to be superior
in treating the negative symptoms compared to other non-clozapine SGAs. The relationship between receptor
pharmacology proﬁles of the antipsychotics and their clinical efﬁcacy is not yet fully understood.© 2013 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The “typical” antipsychotic drugs (ﬁrst generation antipsychotics
(FGAs)) such as haloperidol and chlorpromazine are D2 dopamine
receptor antagonists and have been used to treat schizophrenia
since more than ﬁfty years. To overcome some of the adverse events
(e.g. extrapyramidal side effects) of typical antipsychotics and totics, Toxicology and Targeting,
V Groningen, The Netherlands.
evier OA license.improve the treatment options for the negative symptoms of schizo-
phrenia, second generation antipsychotics (SGAs) or “atypical” anti-
psychotics were introduced into the clinic in 1990s. Unlike FGAs,
SGAs interact with a broader range of pharmacological receptor types.
SGAs with a high afﬁnity mainly towards serotonin and dopamine re-
ceptors (mainly 5-HT2A and D2) were classiﬁed as serotonin–dopamine
antagonists (Horacek et al., 2006) or serotonin spectrum dopamine
modulators (Meltzer and Massey, 2011) (e.g. risperidone, paliperidone,
ziprasidone, asenapine, and lurasidone). In contrast, SGAs that show
an afﬁnity for other receptors such as histaminergic, cholinergic, and
α-adrenergic receptors, in addition to serotonin and dopaminergic
activity are grouped as multi-acting receptor targeted antipsychotics
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Although there are several SGAs available on the market for the treat-
ment of schizophrenia, several unmet needs remain unaddressed,
including a more effective treatment towards the negative symptoms
and cognitive impairment in patients with schizophrenia (Leucht et
al., 2009).
One of the rating scales frequently used to measure the clinical
effect of antipsychotics is the Positive and Negative Syndrome Scale
(PANSS) (Kay et al., 1987). It consists of 30 items, where each item
is scored from 1 through 7 (1 indicating the absence of the symptom
and7 indicating extremely suffering from the symptom). These 30 items
are grouped into 3 subscales; positive (7 items), negative (7 items) and
general psychopathology (16 items).
It has been suggested that SGAs aremore effective towards negative
symptoms than FGAs in schizophrenic patients. However, recently,
Leucht et al. (2009) performed statistical meta-analyses of clinical trials
in patients with schizophrenia and reported a limited advantage of
the newer agents in terms of efﬁcacy towards the negative symptoms.
To complement the ﬁndings of Leucht et al. (2009) in this paper we
present the pharmacokinetic and pharmacodynamic (PKPD)modelling
results for 1 FGA and 4 SGAs, using a large pooled dataset of PK and
PANSS scores from schizophrenic patients. In this analysis, we also
account for the placebo effect, predictors of the placebo effect (via
covariate analysis) and the dropouts (via time-to-event type of hazard
models).
To our knowledge, limited quantitative research has been carried
out to link the exposure of antipsychotic drugs to the total PANSS
score and no literature is available linking the exposure to PANSS sub-
scales per se. Hence, we developed a PKPD model using PANSS total
score and presented the results in an accompanying research article
(part I) (Pilla Reddy et al., 2012, 2013-this issue). In the present paper
(part II), the primary objectivewas to quantify the drug effects towards
the 3 PANSS subscales by PKPD modelling of individual-patient level
placebo and drug response data. In addition, the relationship between
the clinical efﬁcacy, in vitro and in vivo receptor pharmacology proﬁles,
and the dopamine and serotonin receptor occupancy (D2RO and
5-HT2ARO) of antipsychotic drugs was investigated with the aim of in-
vestigating the hypothesis that SGAs show better negative symptom
control than FGAs.2. Methods
This work was performed within the framework of the Dutch Top
Institute Pharma Project: Mechanism-based PKPD modelling platform
(http://www.tipharma.com). This modelling platform involves leading
global pharmaceutical companies and academic institutions from The
Netherlands. PANSS and PK data used in this analysis were provided by
Janssen Research and Development (Belgium), Pﬁzer (USA) and Merck
(The Netherlands) and came from a number of double-blind clinical
trials of their investigational drugs conducted between 1989 and 2009.
Only clinical trial data available to us where scores on all subscales for
individual patients were known was for 4 SGAs (olanzapine, risperi-
done, paliperidone, and ziprasidone) and 1 FGAs (haloperidol). Unfor-
tunately we did not have data for other than haloperidol under FGAs.
With available data, we have compared the effect of SGAs with FGA
(haloperidol) and also among the SGAs. As the PANSS subscale data
was not available for someof the studies, the number of placebo treated
patients in the dataset for PANSS subscale analysis (n=741) were
lower than in the dataset used for the PKPD modelling of PANSS total
score (n=1338). All the studies were industry-sponsored Phase II
and Phase III clinical trials except for one open-label study of haloperi-
dol. The overview of trial design, summary statistics of the respective
PANSS total and subscale scores and dropout rates across the studies
used in the development of exposure-response models are shown in
part I of the accompanying paper.Earlier analysis based on the PANSS total scores from the placebo
arms of schizophrenia trials identiﬁed the best placebo model and sev-
eral predictors for the placebo effect (Pilla Reddy et al., 2012). In this
study, we performed a similar analysis to identify the best performing
placebo model and the predictors that are speciﬁc for the PANSS sub-
scales. The typical value of the maximum drug effect (Emax) for the dif-
ferent drugs was estimated using the PKPD model structure that was
developed earlier for the PANSS total score with minor modiﬁcations
if deemed necessary.
The PKPD model structure is shown in the following equation:
PANSS Score ¼ Baseline PANSS

"
1−Pmax 1−e−
TIME
TDð ÞPOW
  
|{z}
Placebo effect model

 
1− EmaxCss
EC50þCss
 
|{z}
Drug effect model
 1−e−KTTIME
 
|{z}
Delay in drug effect
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The Weibull placebo model (Pilla Reddy et al., 2011) describes the
change of the PANSS score from baseline, which eventually reaches a
plateau. Pmax is the maximum placebo effect, TD is the time to reach
63.2% of the maximum change from baseline, and POW is the shape
parameter. In the drug effect model, the PK model-predicted steady-
state concentration (Css) of the antipsychotic drug is related to the
PANSS score using an Emax model. Emax is the maximum drug effect,
EC50 is the steady-state concentration required to achieve half of
Emax. KT is the rate constant associated with the time required to obtain
the maximum drug effect. The inter-individual variability (IIV) for the
model parameters and a residual unexplained variability (RUV) were
estimated if possible. Using the estimates of PKPD model parameters,
the steady-state effective concentrations (Ceff) necessary to reach the
30% reduction in PANSS score from baseline were computed for each
drug using the following equation:
Ceff ¼ EC50= Emax= 1−PANSS= Baseline PANSS  1−Pmaxð Þð Þð Þ−1ð Þ:
The modelling procedures and calculations of Ceff have been de-
scribed in detail in part I (Pilla Reddy et al., 2013-this issue).
To account for the dropouts, an exponential time-to-event (TTE)
hazard model was utilized. In the ﬁrst part of our study the dropout
event was shown to be linked to the PANSS total. However, to under-
stand the contribution of the each PANSS subscale to the total hazard
of patients dropping out from a trial, the dropout model parameters
were estimated under different scenarios. In the ﬁrst scenario, each
of the PANSS subscale contributions towards the hazard of dropout
was analyzed independently:
Hazard for the dropout event ¼ BHAZ
 exp −BETA1  PANSS subscaleð Þ
BHAZ is the baseline hazard without inﬂuence of predictors, while
BETA is a parameter that relates the probability of a patient dropping
out to one of the PANSS subscores. In the second scenario, the hazard of
a patient dropping out from a trial was estimated by allowing a contri-
bution of each of the subscales:
Hazard for the dropout event ¼
BHAZ  expð− BETA1  PANSS positiveð Þ þ −BETA2  PANSS negativeð Þ
þ −BETA3  PANSS generalð Þ
Þ :
In the ﬁnal scenario, combinations of two PANSS subscales were
explored.
To characterize the relationship between the clinical efﬁcacy (30%
reduction in PANSS subscale score from its baseline value) and D2
(D2RO) and 5-HT2A serotonin receptor occupancy (5-HT2ARO) levels,
we used the following relationship:
RO ¼ ROmax  Ceff= Kdþ Ceffð Þ
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level of antipsychotic drug associated with 50% of maximum RO. Ceff
for an antipsychotic drug to produce a 30% change in PANSS subscale
score from its baseline value is obtained from our ﬁnal PKPD model.
The values of Kd and ROmax for D2 receptor binding were obtained
from literature (de Greef et al., 2011), where an Emax model was ﬁtted
to D2RO and plasma concentrations of different antipsychotics from
PET studies to estimate Kd and ROmax. Since human in vivo Kd values
for 5-HT2A receptor binding were not available, we used in vitro Ki
values for calculations, assuming ROmax to be 100% (Nucci et al.,
2009).
Non-parametric bootstrap and simulation-based visual predictive
check (VPC) plots (as described in the part I) (Pilla Reddy et al.,
2013-this issue) were used as model evaluation tools.
3. Results
3.1. Placebo effect model
The Weibull placebo model was used to account for the placebo
effect. The placebo effect model parameters and predictors that were
associated with the placebo effect on the PANSS subscales are reported
in Table 1. The positive symptoms exhibited a relatively higher degree
of improvement than the negative and the general symptoms. Covari-
atemodelling results indicate that substantial heterogeneity in placebo
effect arises from predictors such as study center, study duration and
disease condition. There was a large effect of study center on the place-
bo effect of the negative subscale, i.e. studies that were conducted out-
side USA exhibited a 134% higher placebo effect (Pmax) for the negative
symptoms (improvement). Moreover, higher RUV in non-USA studies
was observed for all the PANSS subscales.
3.2. Pharmacokinetic and pharmacodynamic model
Steady-state concentrations (Css) of antipsychotic drug predicted
by the PK model (as described in part I) were related to the scores
of the PANSS subscales. A common model (analysis of all atypical
antipsychotic drugs together) was developed for PANSS positive and
general scales, but it was not possible for the negative symptoms as
we encountered numerical difﬁculties to ﬁt the drug effect model.Table 1
Placebo model parameter estimates (with bootstrap 95% CIs)a.
Parameters PANSS po
Weibull placebo model parameters
Baseline PANSS (BASL) 22.8 (22.4
TD (days) (time to reach 63.2% of maximum change from baseline) 15 (13–18
Pmax (maximum placebo effect) 0.094 (0.0
POW (shape parameter) 1.26 (1.06
Covariates on placebo model parametersb
BASL-DIS (acute vs. chronic)c −0.15 (−
Pmax-DIS (acute vs. chronic) −1.15 (−
Pmax-USA (USA vs. non-USA) –
RUV-REG (qd vs. bid) –
RUV-DUR (short vs. long) −0.28 (−
RUV-DIS (acute vs. chronic) 0.43 (0.18
RUV-US (USA vs. non-USA) 0.29 (0.15
Random effects (IIV and RUV)
IIV BASL (CV %) 23 (21–24
IIV Pmax (SD) 0.24 (0.22
IIV- RUV (CV %) 28 (21–35
RUV (SD) 1.94 (1.75
a 95% CI from 1000 bootstrap samples; bid=twice daily; CI=conﬁdence interval; CV: coefﬁcien
variability; POW=shape parameter; RUV=residual unexplained variability; USA=location
and SD=standard deviation.
b Parameter-covariate relationship represents a proportional increase in the parameter va
c Chronic patients had 15% lower PANSS positive BASL score.However, separate analysis (per compound) resulted in successful
estimation of the model parameters. Hence, the PD parameters for the
negative subscale were estimated separately for each antipsychotic
drug. The summary of the PKPD parameter estimates of the different
antipsychotic drugs with their 95% bootstrap conﬁdence intervals are
depicted in Table 2. The maximum drug effect size (Emax) against the
positive subscale was high for the antipsychotic drugs when compared
to other subscales (Table 2). On the other hand, the post-hoc individual
estimate of the effect size (Emax) for the negative symptoms was
highest for olanzapine (Fig. 1a). Olanzapine appeared numerically
superior when compared to other antipsychotic drugs with respect to
all symptom domains of schizophrenia. The time course of the PKPD
model-predicted change from baseline of PANSS total and its subscale
scores for placebo and antipsychotic drugs is displayed in Fig. 1b. All
antipsychotics exhibited a greater overall symptom reduction than
placebo. Different time course trajectories between the PANSS subscales
were observed. The positive symptoms of schizophrenia responded
well to all antipsychotics. The improvement in negative symptoms
was not as large as seen with the other symptom domains. All SGAs
and haloperidol reduced the overall negative symptoms signiﬁcantly
more than placebo treatment. Our analysis showed a delay (t1/2 Emax=
0.693/KT) in achieving half of themaximumdrug effect towards the neg-
ative symptoms of more than 3 weeks for ziprasidone and olanzapine,
while it was about 5 days for haloperidol, risperidone, and paliperidone.
The IIV of the EC50 parameter could not be estimated for the positive and
general scales; hence, the IIVwas ﬁxed to a nominal value of 50% CV. The
IIV for the EC50 of the negative subscale could be estimated and was
found to be large for all antipsychotic drugs. Table 3 summarizes the typ-
ical drug effect parameters across the PANSS total and subscale scores
that were subsequently used to calculate the effective concentrations
and respective effective doses required to achieve 20 or 30% reduction
in PANSS scores from the baseline score.
3.3. Dropout model
The parameter BETA that describes the relationship between the
observed PANSS score and the hazard of a patient dropping out from
a trial was estimated to be highest for the PANSS positive subscale
and lowest for the PANSS negative subscale (Table 4). This indicates
that the probability of a patient dropping out from a trial increasessitive PANSS negative PANSS general
–23.2) 23.9 (23.5–24.3) 45.3 (44.6–45.9)
) 19 (14.8–36.8) 15 (13–18)
58–0.125) 0.052 (0.032–0.076) 0.048 (0.028–0.066)
–1.53) 1.39 (1.51–1.99) 1.32 (1.13–1.54)
0.19 to −0.11) – –
1.57 to −0.82) – –
1.34 (0.49–3.13) –
−0.20 (−0.29 to −0.09) –
0.44 to −0.04) – –
–0.73) – 0.31 (0.1–0.55)
–0.44) 0.64 (0.46–0.87) 0.40 (0.22–0.60)
) 22 (20–23) 18 (16–19)
–0.27) 0.17 (0.15–0.24) 0.21 (0.19–0.23)
) 37 (28–46) 30 (28–40)
–2.14) 1.75 (1.51–1.99) 2.9 (2.5–3.4)
t of variation; DIS: disease type; DUR: study duration; qd=once daily; IIV=inter-individual
of study site (in or outside the USA); PANSS=Positive and Negative Syndrome Scale;
lue by the covariate.
Table 2
Model parameter estimates (with bootstrap 95% CIs) obtained from the PKPD models using the time course of PANSS scoresa.
PKPD model Haloperidol Risperidone Olanzapine Ziprasidone Paliperidone
PANSS positive subscale
BASL PANSS positive 23.3 (22.9–23.6) 22.4 (22.4–22.6) 22.4 (22.4–22.6) 22.4 (22.4–22.6) 22.4 (22.4–22.6)
Emax 0.41 (0.25–0.69) 0.32 (0.28–0.38) 0.43 (0.30–0.78) 0.19 (0.13–0.32) 0.33 (0.28–0.39)
EC50 (ng/ml) 1.2 (0.22–3.12) 9.4 (3.4–21.7) 12.4 (1.2–43.3) 25.5 (2.5–130) 5.84 (1.6–12.3)
KT (1/day) 0.11 (0.07–0.18) 0.048 (0.039–0.057) 0.048 (0.039–0.057) 0.048 (0.039–0.057) 0.048 (0.039–0.057)
IIV Emax (SD) 0.30 (0.22–0.44) 0.25 (0.19–0.29) 0.25 (0.19–0.29) 0.25 (0.19–0.29) 0.25 (0.19–0.29)
RUV as SD (additive) 2.2 (2.0–2.3) 2.0 (1.9–2.1) 2.0 (1.9–2.1) 2.0 (1.9–2.1) 2.0 (1.9–2.1)
PANSS negative subscale
BASL PANSS negative 24.1 (23.7–24.4) 24.7 (24.3–25) 23.8 (23.5–24.2) 23.6 (23.3–23.8) 23.8 (23.5–24.1)
Emax 0.21 (0.11–0.38) 0.14 (0.09–0.15) 0.33 (0.22–0.52) 0.17 (0.06–0.33) 0.15 (0.12–0.20)
EC50 (ng/ml) 6.4 (3.7–13.9) 18.5 (3.3–34) 10.1 (2.2–25) 62 (12–191) 17.3 (11.7–57)
KT (1/day) 0.19 (0.14–0.27) 0.16 (0.12–0.21) 0.028 (0.016–0.05) 0.0073 (0.004–0.015) 0.13 (0.10–0.22)
IIV Emax (SD) 0.25 (0.22–0.38) 0.24 (0.20–0.26) 0.40 (0.22–0.38) 0.30 (0.26–0.44) 0.27 (0.22–0.35)
IIV EC50 (CV%) 269 (162–443) 311 (251–425) 141 (65–313) 192 (138–347) 226 (170–243)
RUV as SD (additive) 2.3 (2.2–2.5) 2.3 (2.2–2.3) 2.2 (2.2–2.3) 2.0 (1.9–2.1) 2.0 (1.9–2.2)##
PANSS general subscale
BASL PANSS general 45.1 (44.6–45.6) 44 (43.7–44.2) 44 (43.7–44.2) 44 (43.7–44.2) 44 (43.7–44.2)
Emax 0.27 (0.17–0.48) 0.19 (0.16–0.23) 0.34 (0.25–0.55) 0.12 (0.07–0.20) 0.24 (0.20–0.30)
EC50 (ng/ml) 2.58 (0.73–6.31) 3.97 (0.49–11.1) 12.2 (2.7–37) 36.4 (13.2–131) 3.07 (0.23–10)
KT (1/day) 0.15 (0.09–0.23) 0.035 (0.021–0.045) 0.035 (0.021–0.045) 0.035 (0.021–0.045) 0.035 (0.021–0.045)
IIV Emax (SD) 0.25 (0.19–0.38) 0.22 (0.18–0.32) 0.22 (0.18–0.32) 0.22 (0.18–0.32) 0.22 (0.18–0.32)
RUV as SD (additive) 3.8 (3.6–4.0) 3.6 (3.5–3.7) 3.6 (3.5–3.7) 3.6 (3.5–3.7) 3.6 (3.5–3.7)
a 95% CI from 1000 bootstrap samples; BASL=Baseline; Emax=maximum drug effect; EC50: steady-state concentration required to achieve half of Emax; RUV=residual
unexplained variability; IIV=inter-individual variability; KT=rate constant associated with the time required to obtain the maximum drug effect; PANSS=Positive and Negative
Syndrome Scale; and SD=standard deviation. IIV EC50 for positive and general scale was ﬁxed to 50% CV, as it was not estimable.
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interaction between the PANSS subscales was allowed, the net con-
tribution of the positive subscale for the hazard of dropout remains
high, but the opposite effect was observed with the PANSS negative
subscale i.e. a decrease in probability of patient dropping out with an
increase in observed PANSS negative scores. Based on the change inFig. 1. a. Box plot showing the post-hoc estimates of maximum drug effect on PANSS negative
change from baseline in PANSS total and its subscales for the placebo and for each drug based
from a trial were predicted using the PKPD model). Green=total PANSS, Blue=positive subsNONMEM objective function value (ΔOFV), the dropout model asso-
ciated with only the PANSS positive score and the dropout model as-
sociated with all subscales (i.e. model with interaction between all
subscales) were selected to perform the model-based simulations to
evaluate the predictability of the joint model (PKPD model and drop-
out model).symptoms by antipsychotics on top of the placebo effect. b. Model predicted percentage
on the original dataset but assuming no dropout (missing PANSS scores due to a dropout
cale, Red=negative subscale, Orange=general subscale.
Fig. 1 (continued).
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The bootstrap re-sampling technique and model-based simula-
tions respectively were used as model evaluation tools to check the
stability and predictability of the model. The median parameter esti-
mates obtained from the bootstrap replicates were in agreement
with those obtained with the ﬁnal PKPD model using the original
dataset (data not shown). However, the bootstrap 95% conﬁdence in-
tervals of EC50 for some drugs vary more than 2-fold from the median
typical value (Table 2). Monte-Carlo simulation-based visual predictive
check (VPC) plots indicated that the PKPD models of PANSS subscales
were able to describe the time course of each subscale well. Table 2
and Fig. 2 show the robustness and predictive power of the developed
PKPDmodel, respectively. VPC plots for the joint PKPDmodel including
dropout are shown in Fig. 2a and b. Based on VPC plots, the dropoutmodel with interaction seems to be better in describing the change in
PANSS positive scores following the placebo treatment (97.5th percen-
tiles of the simulated data of Fig. 2b). This ﬁndingmay not be surprising
as placebo arms had higher dropout rates (~65%, mainly due to lack of
efﬁcacy) than the drug treatment arms (~35%) allowing the dropout
model with interaction to perform better for the placebo treatment.
3.5. Relationship between the clinical efﬁcacy and in vitro and in vivo
receptor proﬁles
Tables 5a and 5b summarize the in vitro and in vivo pharmacody-
namic characteristics of antipsychotics, respectively. Olanzapine has
the lowest 5-HT2A/D2 receptor afﬁnity ratio compared to other SGAs.
Based on Ceff values obtained from the model of PANSS total scores, the
calculated D2RO of antipsychotic drugs was in the range of 50–79%,
Table 3
Calculated effective antipsychotic dose and concentrations for PANSS total, and its subscales at 20 and 30% reduction in PANSS score from baseline.
PKPD model estimated parameters Effective Css (ng/ml) Corresponding dose: effective dose
(mg/day)=Css∗CL/F
Baseline score Pmax Emax EC50 20% decrease in PANSS 30% decrease in PANSS 20% decrease in PANSS 30% decrease in PANSS
Haloperidol
PANSS total 91.6 0.081 0.31 3.6 0.84 2.7 1.8 5.6
Positive subscale 23.4 0.099 0.41 1.2 0.17 0.54 0.4 1.2
Negative subscale 24.1 0.047 0.21 6.4 5.8 31 12 65
General subscale 45.1 0.048 0.27 2.58 1.19 3.2 2.51 7.1
Risperidone
PANSS total 91.1 0.073 0.23 3.72 1.38 5.3 0.20 0.8
Positive subscale 22.5 0.094 0.32 9.42 1.68 6.0 0.24 0.9
Negative subscale 24.1 0.051 0.14 18.5 42.1 # 6.3 #
General subscale 44 0.052 0.19 3.97 7.21 # 1.1 #
Olanzapine
PANSS total 91.1 0.073 0.39 24.8 4.89 13.8 2.58 7.3
Positive subscale 22.5 0.094 0.43 12.4 1.52 4.9 0.80 2.6
Negative subscale 24.1 0.051 0.33 10.1 4.9 13.4 2.61 6.38
General subscale 44 0.052 0.34 12.2 3.72 9.2 1.96 4.9
Ziprasidone
PANSS total 91.1 0.073 0.22 39.7 15.6 63.1 20.26 81
Positive subscale 22.5 0.094 0.19 25.5 8.70 48.3 11.27 63
Negative subscale 24.1 0.051 0.17 62 82.8 # 113 #
General subscale 44 0.052 0.12 36.4 # # # #
Paliperidone
PANSS total 91.1 0.073 0.23 6.89 2.55 9.8 0.86 3.3
Positive subscale 22.5 0.094 0.33 5.84 1.00 3.5 0.34 1.2
Negative subscale 24.1 0.051 0.15 17.3 30.0 # 10.4 #
General subscale 44 0.052 0.24 3.07 3.20 22.6 1.05 7.6
PANSS total parameters are from part I (Pilla Reddy et al., 2013-this issue); # 20% or 30% decrease in PANSS from baseline PANSS scorewas not attained. Effective Css (Ceff)=EC50/(Emax/
(1−PANSS/(Baseline PANSS∗(1−Pmax)))−1); % change in score is given by=PANSS−Baseline PANSS/(Baseline PANSS−number of PANSS itemsa) Pmax=maximum placebo
effect; Emax=maximum drug effect; EC50: steady-state concentration required to achieve half of Emax.
a Number of PANSS items: PANSS total: 30; PANSS positive: 7; PANSS negative: 7; PANSS general:16.
158 V. Pilla Reddy et al. / Schizophrenia Research 146 (2013) 153–161which is close to the antipsychotic D2RO therapeutic window of 60–80%.
The level of D2RO required for improving the positive symptoms was in
the range of 42–74%.
Olanzapine was quite different in terms of in vivo PD characteristics
when compared to other SGAswith the lowest D2RO for both the positive
(42%) and for the negative symptoms (42%). Haloperidol was distinct
from SGAs with a lower 5-HT2A/D2 receptor afﬁnity ratio and low
5-HT2ARO levels. In line with the reported in literature (Kapur et al.,
1996), Tables 5a and 5b show that haloperidol predominately binds
to the dopamine (D2) receptors, while olanzapine moderately binds
to D2 and 5-HT2A receptors, which makes it atypical in terms of recep-
tor proﬁles. This atypical receptor proﬁle of olanzapine may be related
to improvement of the negative symptoms of schizophrenia.Table 4
Results of joint modelling of PANSS scores and the dropout events.
Parameters (% RSE) Scale
PANSS total Positive Negative General Positiv
BHAZ:
Placebo (1/day) 0.0005 (9) 0.00119 (7) 0.00438 (8) 0.00057 (9) 0.0006
Risperidone (1/day) 0.00031 (10) 0.00072 (7) 0.00219 (9) 0.00038 (9) 0.0004
Olanzapine (1/day) 0.00046 (11) 0.00096 (10) 0.00304 (10) 0.00054 (11) 0.0006
Ziprasidone (1/day) 0.00022 (8) 0.00054 (7) 0.00157 (8) 0.00023 (9) 0.0003
Paliperidone (1/day) 0.00057 (9) 0.00119 (8) 0.00409 (9) 0.00067 (9) 0.0007
BETA −0.0352 (3) NE NE NE NE
BETA1 (positive) NE −0.111 (3) NE NE −0.07
BETA2 (negative) NE NE −0.0443 (6) NE 0.0312
BETA3 (general) NE NE NE −0.0672 (4) −0.04
OFV 112,211 112,102 112,952 112,212 111,94
ΔOFV – −109 +741 +1 −271
NE: not estimated; ΔOFV: Change in OFV in relation to the PANSS total model; BHAZ: baseli
dropping out from a trial increased exponentially with increasing PANSS score.4. Discussion
SGAs are claimed to exhibit a broad efﬁcacy spectrum with lesser
side effects than FGAs. One of the assertions while marketing these
SGAs is “better negative symptom control than FGAs” (Sernyak and
Rosenheck, 2007). SGAs are different from conventional typical anti-
psychotics in many ways including their receptor binding properties,
efﬁcacy and safety proﬁles. The available SGAsmight be effective against
different symptomdomains other thanpositive symptomsdepending on
their receptor binding proﬁle (Grunder et al., 2009). It has been hypoth-
esized that either a higher 5-HT2A/D2 afﬁnity ratio or a high selectivity to-
wards the 5-HT2A receptors contributes to the improved efﬁcacy towards
the negative symptoms in schizophrenia (Kapur and Remington, 1996).e+negative+general Positive+negative Positive+general Negative+general
6 (10) 0.00112 (9) 0.00053 (9) 0.00076 (9)
6 (10) 0.00068 (9) 0.00036 (9) 0.00053 (9)
1 (12) 0.0009 (12) 0.00049 (11) 0.00072 (11)
(9) 0.00051 (9) 0.00024 (9) 0.00031 (9)
4 (9) 0.00113 (9) 0.0006 (9) 0.00087 (9)
NE NE NE
03 (5) −0.11 (3) −0.0746 (5) NE
(13) −0.00382 (86) NE 0.0422 (9)
79 (6) NE −0.0342 (7) −0.0831 (7)
0 112,101 111,980 112,138
−110 −231 −73
ne hazard without inﬂuence of predictors; BETA: indicates that probability of a patient
Fig. 2. Depicts the visual predictive check (VPC) plots of the PKPD model for different antipsychotics with the dropout model using observed PANSS positive scores (top panel) and the dropout model using observed scores of all subscales
i.e., positive+negative+general (bottom panel). The gray shaded areas represent the 95% conﬁdence intervals of the corresponding 2.5th, 50th and 97.5th percentiles of the simulated data, the black dashed lines represent the 2.5th and
97.5th percentiles of the observed data and the black solid line represents the median of the observed data. Black dots represent the observed PANSS scores.
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Table 5a
In vitro pharmacodynamic characteristics of antipsychotics.
Antipsychotic
drug
D2 (koff: min−1)
Kapur and Seeman
(2000)
In vitro receptor afﬁnity (Ki in nM)
D2 5-HT2A 5-HT1A 5-HT2C 5-HT2A/D2
Haloperidol 0.017 2 119 2832 4475 59.5
Risperidone 0.026 4.9 0.48 420 33 0.10
Olanzapine 0.039 72 4.9 2720 14 0.07
Ziprasidone 0.073 4 0.73 112 4.1 0.18
Paliperidone 0.026a 2.1 1 590 NA 0.48
Lower 5-HT2A/D2 afﬁnity ratio indicates higher the selectivity towards 5-HT2A, koff=
dissociation constant for D2 receptor.
a Same as that of risperidone.
160 V. Pilla Reddy et al. / Schizophrenia Research 146 (2013) 153–161The 5-HT2A antagonism may confer atypicality on antipsychotic drugs
with relatively weaker D2 antagonism because of the ability of 5-HT2A
receptors tomodulate the activity of dopaminergic neurons differentially
in different regions of the brain (Meltzer et al., 2003).
A meta-analysis of clinical studies using a central tendency statis-
tical approach may account for some sources of variability in efﬁcacy
but may not provide sufﬁcient information from a drug development
perspective about the efﬁcacy, potency, and safety of a drug. Never-
theless, it may provide information about the potential of a drug to
be effective against the given condition. On the contrary, population-
based PKPD modelling using non-linear mixed effect approach is very
well suited to handle the different sources of variability that eventually
helps to strengthen the claim for efﬁcacy and provides quantitative es-
timates of time course and magnitude of drug action. PKPD modelling
allows estimating the effectiveness of SGAs after accounting for the
differences related to methodological aspects, exposure, placebo effect,
and dropout rates. Investigations into the PANSS subscales and com-
ponents of the PANSS using advanced methodological approaches
such as modelling and simulations could provide a means for a better
understanding of diverse therapeutic aspects of SGAs. For this reason,
we applied a PKPDmodelling approach using the data obtained for the
different PANSS subscales to differentiate between antipsychotic drugs
with respect to their effect on different domains of schizophrenia
reﬂected by the different PANSS subscales. In addition, the relationship
between the clinical efﬁcacy, in vitro and in vivo receptor pharmacology
proﬁles was explored. The comparison of the time course of the effect
of the drugs on the different subscales showed appreciable differences.
All antipsychotic drugs were more effective than placebo during the
ﬁrst 2 weeks of the study (Fig. 1b). In our PKPD analysis, the time re-
quired to achieve half of the maximum drug effect (Emax) for positive
and general symptoms for SGAs was found to be about 2–3 weeks.
Some neuronal remodelling changes in the brain may be responsible
for this gradual increase to the maximum drug effect (Horacek et al.,
2006). On the contrary, this time delay to achieve half of themaximum
drug effect was less than one week with haloperidol treatment. This
faster improvement with haloperidol treatment may be due to its quick
blockade of the D2 receptor to cause an antipsychotic action and slow
koff rates from D2 receptors (Stahl, 2008).Table 5b
Relationship between the effective concentrations (Ceff) and the receptor occupancy levels
Antipsychotic
drug
ROmax D2RO
de Greef et al. (2011)
Kd: D2 (ng/ml)
de Greef et al. (2011)
Kd: 5-HT2A (ng/ml)
Nucci et al. (2009)
Ce
To
Haloperidol 92 0.53 13.5 2
Risperidone 91 4.43 0.07 5
Olanzapine 88 5.29 1.25 13
Ziprasidone 98 15.4 1.97 63
Paliperidone 90 4.6 0.09 9
a Corresponds to 20% decrease in PANSS score from baseline as the maximum improvem
Kd=plasma level of antipsychotic drug associated with 50% of maximum RO; Ceff=drug c
occupancy; 5-HT2A RO=serotonin 2A receptor occupancy.The negative subscale appears to have a lower magnitude of
improvement when compared to other subscales (Fig. 1b). The delay
in achieving the maximum drug effect for the negative symptoms was
reported before in the literature (King, 1998a, 1998b). With our data,
haloperidol, risperidone, and paliperidone showed slightly faster
onset of drug effect or improvement for the negative symptoms than
ziprasidone and olanzapine.
Joint modelling of PANSS total scores with dropout events using the
placebo data and antipsychotic drugs showed that the relationship
between the chance of a patient dropping out of a trial increases with
lack of improvement in schizophrenia symptoms (Pilla Reddy et al.,
2012, 2013-this issue). When the results were analyzed for the different
PANSS subscales it appeared that the probability of a dropout was
more strongly associated with worsening of positive symptoms
(BETA=−0.11) than of negative and general symptoms. Although
dropout modelling using only the PANSS for the negative symptoms
showed that the hazard of dropout increases with worsening of nega-
tive symptoms (BETA=−0.044), the increase in NONMEM OFV by
741 units relative to PANSS total indicates a poor association between
the negative subscale and the dropout event. When interaction be-
tween the PANSS subscales was allowed in the model, an opposite ef-
fect was observed with the PANSS negative subscale i.e. a decrease in
probability of a patient dropping out was found to be correlated with
an increase in observed PANSS negative scores. The physiological rea-
son for thisﬁnding is difﬁcult to understand, but itmay be hypothesized
that this effect could be due to secondary effects of an improvement of
positive and general symptoms, or a reduction of co-morbid symptoms
of depression or anxiety, or an alleviation of the extrapyramidal effects
by co-medication (e.g. anti-cholinergic agents). Moreover, less im-
provement in negative symptoms may lead to hospitalization of the
patient, which may result in lower dropout rates. We did not have
co-medication information for all the trials to explore the effect of
adjunctive therapy for the improvement of negative symptoms. How-
ever, Ahadieh et al. (2011) reported that adjunct therapy in schizo-
phrenia does affect the improvement in the time course of PANSS
negative symptoms.
It has been suggested that complex pharmacological interactions
between several receptors are important for atypicality. Table 5a supports
the hypothesis that the afﬁnity (ki) ratio of serotonergic activity to dopa-
minergic activity (Meltzer et al., 1989, 2003) plays a role to some extent
in mediating the efﬁcacy of atypical antipsychotics (e.g. olanzapine). The
calculated D2RO levels required for the improvement in PANSS total
score were in the range of 50–79%, which is more or less in line with
suggested D2RO range (Uchida et al., 2011). However, our data suggest
that different levels of D2 and 5-HT2A receptor occupancy are required
to achieve improvement in PANSS subscales (Table 5b). Relatively high
afﬁnity towards serotonin receptor subtypes could potentially enable
a compound to produce antipsychotic efﬁcacy at lower levels of D2 oc-
cupancy (de Greef et al., 2011).
Recently, Frankle et al. (2011) showed the relationship between
the 5-HT1A receptor binding and the improvement in negative symp-
toms following ziprasidone dosing (n=6). However, in our analysis,.
ff (ng/ml) D2RO (%) 5-HT2A RO (%)
tal Positive Negativea Total Positive Negative Total Positive Negative
.7 0.54 5.8 77 46 84 17 4 30
.3 6 42.7 50 52 83 99 99 100
.8 4.9 4.9 63 42 42 92 80 80
.1 48.3 83 79 74 83 97 96 98
.8 3.5 30 61 39 78 99 97 100
ent of >20% with PANSS score never attained. ROmax=maximum receptor occupancy,
oncentration to produce a 30% reduction in PANSS score; D2RO=dopamine 2 receptor
161V. Pilla Reddy et al. / Schizophrenia Research 146 (2013) 153–161ziprasidone exhibited a low effect towards the negative symptoms
raising the question about the role of 5-HT1A receptors towards the
improvement of negative symptoms.
This pooled analysis of the efﬁcacy of several SGAs and one FGA
concludes that atypical antipsychotics are not superior to the high po-
tency typical antipsychotic haloperidol with respect to improvement
of the scores for the diverse subscales of the PANSS. However, olanzapine
due to its different pharmacological proﬁles compared to other SGAs
is shown to result in a better negative symptom management. The
strength of our pooled PKPD analysis is that we could compare the
differences in efﬁcacy within the atypical antipsychotics and with the
typical antipsychotic haloperidol. Extrapolation to other antipsychotics
namely, asenapine (Friberg et al., 2009), quetiapine (Kimko et al.,
2000) and lurasidone using their respective efﬁcacy PD parameters
from literature by means of Ceff=EC50/(Emax/(1−PANSS/(Baseline
PANSS×(1−Pmax)))−1) resulted in Ceff and effective doses (data not
shown), which were in line with reported in literature or regulatory
documents.
Adverse events such as extrapyramidal side effects were not taken
into account despite the fact that they potentially could negatively
inﬂuence the efﬁcacy outcomes. Therefore, the value of this PKPD
analysis can be further improved by integration of adverse event
modelling results. The relationship between receptor pharmacology
proﬁles of the antipsychotics and their clinical efﬁcacy is not yet
fully understood. In this regard, PKPD modelling could be a valuable
tool to characterize the relationship between D2RO and clinical effects
of antipsychotic drugs and to predict the optimal human dose for new
antipsychotic drugs.
In this modelling work, we have taken into consideration of factors
such as the drug's afﬁnity and intrinsic activity at the site of action,
drug concentration and underlying internal and external factors of the
patient to determine the effective dose and concentration that lead to
better antipsychotic efﬁcacy. Such an analysis enhances the key deci-
sions in drug development such as dose selection, study design, product
positioning, in-licensing, and early go/no-go decisions. In conclusion,
this PKPD modelling work may be helpful to differentiate the effects
of antipsychotic drugs across the different symptom domains of acute
and chronic schizophrenia, accounting for placebo effect and dropouts.
Our analysis revealed that olanzapine seems to be superior in treating
the negative symptoms compared to other non-clozapine SGAs.
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